[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7037 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 7037

    To provide for quality assurance of COVID-19 reimbursements and 
                               reporting.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 27, 2020

  Mr. Posey introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
   the Judiciary, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
    To provide for quality assurance of COVID-19 reimbursements and 
                               reporting.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. QUALITY ASSURANCE OF COVID-19 REIMBURSEMENTS AND REPORTING.

    (a) In General.--Notwithstanding any other provision of law, no 
Federal funds shall be used for a reimbursement or payment for--
            (1) COVID-19 testing of any individual unless the request 
        for such reimbursement or payment is accompanied by evidence 
        that the individual was tested using a test that was approved, 
        cleared, or authorized under section 510(k), 513, 515, or 564 
        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(k), 
        360c, 360e, 360bbb-3) for COVID-19 diagnosis; or
            (2) COVID-19 treatment of any individual unless the request 
        for reimbursement or payment is accompanied by evidence that 
        the person tested positive for COVID-19 using a test that was 
        approved, cleared, or authorized under section 510(k), 513, 
        515, or 564 of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 360(k), 360c, 360e, 360bbb-3) for COVID-19 diagnosis.
    (b) Quality Assurance of Reimbursements.--For purposes of 
subsection (a), notwithstanding any other provision of law, the head of 
any Federal agency authorized to make a reimbursement or payment for 
COVID-19 testing or treatment of individuals shall review each request 
presented for such reimbursement or payment and--
            (1) deny any request for such a reimbursement or payment 
        for COVID-19 testing of an individual or, if reimbursement or 
        payment has already been made, cause to be recovered such 
        reimbursement or payment, unless the request is accompanied by 
        evidence that the individual was tested using a test that was 
        approved, cleared, or authorized under section 510(k), 513, 
        515, or 564 of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 360(k), 360c, 360e, 360bbb-3) for COVID-19 diagnosis as 
        of the date of the review of the head of the agency;
            (2) deny any request for such a reimbursement or payment 
        for COVID-19 treatment of an individual or, if reimbursement or 
        payment has already been made, cause to be recovered such 
        reimbursement or payment, unless the request is accompanied by 
        evidence that the individual tested positive for COVID-19 using 
        a test that was approved, cleared, or authorized under section 
        510(k), 513, 515, or 564 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 360(k), 360c, 360e, 360bbb-3) for 
        COVID-19 diagnosis as of the date of the review of the head of 
        the agency; and
            (3) provide to the Director of the Centers for Disease 
        Control and Prevention the results of such review.
    (c) Correction of Reports.--The Director of the Centers for Disease 
Control and Prevention shall apply the results provided to the Director 
under subsection (b)(3) to--
            (1) exclude from the official United States count of cases 
        of COVID-19 any individual reported to have been positive for 
        COVID-19 in a request subject to review in subsection (b) but 
        where the agency head involved found the request was not 
        accompanied by evidence that the individual had been tested 
        positive for COVID-19 using a test that was approved, cleared, 
        or authorized under section 510(k), 513, 515, or 564 of the 
        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(k), 360c, 
        360e, 360bbb-3) for diagnosis of COVID-19; and
            (2) exclude from the official United States count of deaths 
        due to COVID-19 any individual who died and was reported to 
        have been treated or tested positive for COVID-19 in a request 
        subject to review under subsection (b) but where the agency 
        head involved found the request was not accompanied by evidence 
        that the individual had been tested positive for COVID-19 using 
        a test that was approved, cleared, or authorized under section 
        510(k), 513, 515, or 564 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 360(k), 360c, 360e, 360bbb-3) for 
        diagnosis of COVID-19.
    (d) Penalty.--Any person who knowingly reports a false diagnosis of 
COVID-19 shall be imprisoned not more than 10 years and fined under 
title 18, United States Code, or both.
                                 <all>